Navigation Links
Daiichi Sankyo's Once-Daily Edoxaban Meets Primary Efficacy Endpoint for Stroke Prevention and Superiority for the Principal Safety Endpoint Compared to Warfarin for Patients with Atrial Fibrillation in a Phase 3 Clinical Trial
Date:11/19/2013

atment and prevention of recurrence of venous thromboembolism (VTE) in patients with deep vein thrombosis (DVT) and/or pulmonary embolism (PE), and for the prevention of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation, respectively.1,2,8

Edoxaban is currently approved only in Japan, since April 2011, for the prevention of VTE after major orthopedic surgery, and was launched in July 2011 under the brand name Lixiana®. Elsewhere, including Europe and the US, edoxaban is currently in phase 3 clinical development and has not been approved in any indication.9 Results from the Hokusai-VTE clinical trial were presented at the European Society of Cardiology Congress on September 1, 2013 and published in the New England Journal of Medicine.8,9

About Daiichi Sankyo 

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit: www.daiichisankyo.com.

Contact
Michaela Paudler-Debus, PhD
Daiichi Sankyo Europe
michaela.paudler-debus@daiichi-sankyo.eu 
+49 89 7808 685 (office)
+49 176 11780966 (mobile)

<
'/>"/>
SOURCE Daiichi Sankyo
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
2. Daiichi Sankyo CEO John Gargiulo Elected as National Pharmaceutical Councils Chairman of the Board
3. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il più ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
4. Daiichi Sankyo Completes Enrolment in Hokusai - VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE
5. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
6. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
7. Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
8. Sosei Group Corporation: QVA149 Filed by Licensing Partner as a Once-Daily Maintenance Treatment for COPD in Japan
9. Sosei Group Corporation: QVA149 Filed as a Once-Daily Maintenance Treatment for COPD in Europe
10. Sosei Group Corporation: Data at ERS Shows Efficacy of Once-daily COPD Portfolio Versus Comparators, Further Establishes Dual-bronchodilator QVA149
11. Coherus Announces CHS-0214 (Proposed Etanercept Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... PuraMed BioScience®, Inc., (OTC Pink: PMBS), a ... healthcare products, announced it received the initial funding to ... headache relief product, for planned distribution to 1,000 medical ... , Washington State , and ... H Advanced headache relief gel formulation completed, PuraMed BioScience ...
(Date:12/24/2014)... Dec. 23, 2014 ResMed (NYSE: RMD ... action against Chinese medical device manufacturer BMC Medical Co., Ltd. ... that BMC,s masks listed below infringe ResMed,s patents, and entered ... masks in the United States : ... mask , Willow nasal pillows mask , iVolve ...
(Date:12/24/2014)... , Dec. 23, 2014   Assurex Health, ... support to healthcare providers for behavioral health and ... secured $30 million in equity financing from new ... Drosos , President and Chief Executive Officer. ... and development of Assurex Health,s GeneSight ® ...
Breaking Medicine Technology:PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4
... Oct. 6 BioTrends Research Group, Inc. recently published ... This report is ... practice in China and qualitative interviews conducted with ten ... of nephrology practice in China and focuses specifically on ...
... (Nasdaq: ARAY ), a global leader in ... patient has been treated with the CyberKnife ® ... the treatment of both cancerous and non-cancerous tumors anywhere ... CyberKnife radiosurgery received treatment during Accuray,s fiscal 2010, which ...
Cached Medicine Technology:New Report by BioTrends Examines the Treatment of Renal Anemia in China 2100,000th Patient Treated With Accuray's CyberKnife® Robotic Radiosurgery System 2100,000th Patient Treated With Accuray's CyberKnife® Robotic Radiosurgery System 3
(Date:12/25/2014)... (PRWEB) December 26, 2014 The ... CAGR of 7.2% to reach $5,756.0 million by ... the microscopy market. The electron microscopes product segment ... the forecast period. , Rising focus on nanotechnology, ... growth of the microscopy market. , Get Full ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... December 26, 2014 The report “TS-1 ... focuses on the current treatment landscape, unmet needs, current ... TS-1 is an anti-cancer drug which is typically used ... is also used for treating gastric cancer and pancreatic ... potassium. The drug was first approved in 1999 in ...
(Date:12/25/2014)... “Every three months the trends for evening dresses ... be one of the hottest styles in the next few ... company releases 26 A-line sweetheart evening dresses, and announces the ... “We are trying our best to help a lady to ... with affordable prices, we provide discounted delivery costs to our ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online ... its collection of discounted prom dresses, most of which ... spokesman of the company, the promotion is valid until ... to expand the UK market. , The prom dresses ... lengths, and styles: A-line strapless, empire strapless chiffon, one ...
Breaking Medicine News(10 mins):Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2
... point to death from TB, not Addison,s, researcher says ... Pride and Prejudice and Emma ... has long been believed, says one British scholar. , Since ... many historians and other experts have believed the cause was ...
... ... price transparency and patient estimations. , ... Denver, CO (PRWEB) December 2, 2009 -- Financial Healthcare Systems (FHS Corp) announced today ... for revenue cycle, finance and registration hospital personnel. The inaugural event will occur on ...
... , , CHICAGO, Dec. 2 , ... , A special press briefing will be held Wednesday, Dec. ... panel of top experts who will discuss the recent U.S. ... guidelines. Many patients, breast cancer survivors, medical experts and government ...
... ... the 86th president of the National Dental Association (NDA) at 6 p.m. on December 5 ... ... R. Owens will be installed as the 86th president of the National Dental Association (NDA) ...
... ONDAMED® ... ... In her new book KNOCKOUT, Interviews with Doctors Who Are Curing Cancer, And How to ... the most innovative cancer treatments--treatments that build up the body rather than tear it down. ...
... ... released his first full-length book, Short White Coat: Lessons from Patients on Becoming a Doctor, ... , ... December 2, 2009 -- Most people will, at some point or another, either find themselves ...
Cached Medicine News:Health News:New Light on Jane Austen's Final Chapter 2Health News:FHS Corp Announces Price Transparency Webinar Series 2Health News:Wednesday, Dec. 2: News From the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) in Chicago 2Health News:Wednesday, Dec. 2: News From the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) in Chicago 3Health News:Meharry Medical College Officer Will Head the National Dental Association 2Health News:Meharry Medical College Officer Will Head the National Dental Association 3Health News:Innovative Biofeedback Technology Wins By A "Knockout." 2Health News:Innovative Biofeedback Technology Wins By A "Knockout." 3Health News:Innovative Biofeedback Technology Wins By A "Knockout." 4Health News:Beneath the Short White Coat: A Medical Student Reveals All 2
... Solution offers relief from CTS pain and ... from other over-the-counter CTS treatments. It is ... sleep, the Carpal Solution gently reshapes soft ... and eliminates hand pain, numbness and sleep ...
... ESR-10 Manual Rack is a manual ... the erythrocyte sedimentation rate (ESR) of ... 1.2ml Streck ESR-Vacuum Tubes. The rack ... simultaneously. The ESR-10 Manual Rack exhibits ...
... assayed control for immunophenotyping with Beckman Coulter® ... the accuracy and reproducibility of all the ... including red blood cell lysis. Reference values ... lymphocytes, B lymphocytes, granulocytes, monocytes, and NK ...
... Cyto-Chex is a storage ... preserve the white blood cells ... activity of antigenic sites. Samples ... stored for up to seven ...
Medicine Products: